TScan Therapeutics Shares Take Flight on Amgen Pact
By Colin Kellaher
TScan Therapeutics shares surged on Tuesday after the clinical-stage biopharmaceutical company said it entered a collaboration potentially worth more than $500 million with biotechnology company Amgen.
Shares of Waltham, Mass.-based TScan were recently changing hands at $3.32, up nearly 48%, in early trading.
TScan said it would receive an upfront payment of $30 million from Amgen, adding that it could earn more than $500 million in success-based milestone payments, along royalty payments on sales of products developed from the collaboration.
TScan and Amgen, based in Thousand Oaks, Calif., said they would work together to discover new targets for the chronic inflammatory bowel disorder Crohn's disease.
TScan ended 2022 with $120 million in cash and equivalents.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 09, 2023 09:53 ET (13:53 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Target Stock a Buy, Sell, or Fairly Valued?
-
Obesity Drug Stocks: Where to Invest Now
-
How to Invest Like Warren Buffett
-
DuPont Split Gives Investors Better Choices
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy